Starpharma today announced successful completion of the phase 1 component of its phase 1 / 2 trial for DEP^® cabazitaxel. The trial met its objective of evaluating safety, tolerability and preliminary efficacy data, and identifying a recommended phase 2 dose of 20 mg/m². The trial will now transition seamlessly into phase 2, with two new sites initiated and recruitment activities already underway.

Melbourne, Australia: Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 4.00pm today.

Starpharma today announced that it has been granted marketing approval for the VivaGel^® condom in Europe.  

Starpharma today notifies that its 2019 AGM will be held at 4pm on 21 November 2019 at RACV City Club, Level 2, 501 Bourke Street, Melbourne, Victoria.

The AGM will be recorded and available via webcast later that day. To access the webcast, participants can register via the following link:

https://webcasting.boardroom.media/broadcast/5dccc1f06242591605116cb6

Starpharma today announced that VivaGel^® BV has been launched in the UK under the brand Betafem^® BV Gel. This launch follows the first European launches in June 2019, including in Germany and other countries.

The Austraian published an interview with Starpharma CEO Dr Jackie Fairley where she discussed the potential of the dendrimer technology, how it is applied to cancer drugs and the potential benefits it provides to patients.

To read the full article, click here. (paywall)

Online pharmaceutical publication Pharma in Focus noted Starpharma’s positive DEP^® gemcitabine results in a human pancreatic model, noting it was one of multiple DEP^® drugs from the company.

To read the full article, click here.

Starpharma today announced results for its next internal development candidate, DEP^® gemcitabine.

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2019.

Starpharma’s cash balance as at 30 September 2019 was $36.8 million, with net operating cash outflows for the quarter of $4.6 million. The cash balance does not include the anticipated $4.9 million R&D tax incentive which is expected to be received during the December quarter.

Starpharma today announced that it has been invited once more to present at the 9th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston, USA, on 7-8 October.

The PODD conference showcases the latest advances in drug delivery and provides networking opportunities with senior scientific and commercial executives from many of the major international pharmaceutical companies. This year’s PODD conference will be chaired by AstraZeneca’s Head of Drug Delivery, Dr Shawn Davis.